Ellagic acid reduces UV damage in mice

30 April 2009

Using a topical application of ellagic acid, an antioxidant found in berries, South Korean researchers markedly prevented collagen  destruction and inflammatory response - a major cause of wrinkles - in  both human skin cells and the sensitive skin of hairless mice following  continuing exposure to UV-B, the sun's skin-damaging ultraviolet rays.

Scientists from the Hallym University in South Korea found that, in  human skin cells, ellagic acid worked to protect against UV damage by  blocking production of MMP - matrix metalloproteinase enzymes that break  down collagen in damaged skin cells - and by reducing the expression of  ICAM, a molecule involved in inflammation.

The scientists investigated young, male, hairless mice - genetically  bred for use in dermatology studies because of the physiological  similarities of their skin to that of humans. For eight weeks, the 12  mice were exposed to increasing levels of ultraviolet radiation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight